Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ZIMMER BIOMET HOLDINGS, INC. incurred senior notes of $500.0 million aggregate principal amount with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC at 5.350% per annum maturing December 1, 2028.
- Instrument
- senior notes
- Principal
- $500.0 million aggregate principal amount
- Counterparty
- Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC
- Rate
- 5.350% per annum
- Maturity
- December 1, 2028
- Event
- incurrence
Exact text from the filing
USA LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $500.0 million aggregate principal amount of the Company’s 5.350% Note due 2028 (the “Notes”). The issuance of the Notes was completed on December 1, 2023. The Underwriting Agreement contains
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZIMMER BIOMET HOLDINGS, INC. entered into Underwriting Agreement with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC valued at $500.0 million aggregate principal amount (effective 2023-11-28).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC
- Value
- $500.0 million aggregate principal amount
- Effective
- 2023-11-28
Exact text from the filing
On November 28, 2023, Zimmer Biomet Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $500.0 million aggregate principal amount of the Company’s 5.350% Note due 2028 (the “Notes”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZIMMER BIOMET HOLDINGS, INC. entered into Ninth Supplemental Indenture with Computershare Trust Company, N.A. (effective 2023-12-01).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- Computershare Trust Company, N.A.
- Effective
- 2023-12-01
Exact text from the filing
The Notes were issued pursuant to the Ninth Supplemental Indenture dated as of December 1, 2023 (the “Supplemental Indenture”), to the Company’s Indenture (the “Base Indenture”) dated as of November 17, 2009, between the Company and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee.
View on SEC.gov